New Target Identified to Limit Triple-Negative Breast Cancer Spread
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Hidden brake: In triple-negative breast cancer, a low level of micro-RNA miR-342 can go hand in hand with a particularly metastatic tumor program. Researchers have now shown that miR-342 dampens the E2F pathway and slows the growth of scattered cancer cells in mouse models. Palbociclib, the CDK4/6 inhibitor that has already been used, has followed the same pathway, but clinical tests are still pending. Adelaide (Australia). Triple-negative breas…
LSD1 Expression is Associated with Immune Exclusion and Hypoxia-Related Transcriptional Programs in Triple-Negative Breast Cancer
Background Triple-negative breast cancer (TNBC) exhibits aggressive biology and heterogeneous immune infiltration. Lysine-specific demethylase 1 (LSD1/KDM1A) is an epigenetic regulator implicated in oncogenic transcriptional programs; however, its association with hypoxia signaling an...
Triple-negative breast cancer often metastases and does not respond to many therapies. But now researchers have identified a potential vulnerability.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
